Stockscreener 앱 받기
329.77
2.39%
7.71
시간 외 거래:
329.77
전일 마감가:
$322.06
열려 있는:
$319.62
하루 거래량:
967.74K
Relative Volume:
0.96
시가총액:
$39.44B
수익:
$2.35B
순이익/손실:
$-269.70M
주가수익비율:
-157.78
EPS:
-2.09
순현금흐름:
$-75.39M
1주 성능:
+2.43%
1개월 성능:
+7.74%
6개월 성능:
+41.16%
1년 성능:
+33.18%
1일 변동 폭
$319.40
$330.00
1주일 범위
$315.00
$330.00
52주 변동 폭
$205.87
$330.00
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Alnylam Pharma Appoints New Chief R&D Officer - TipRanks
Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer - MarketScreener
Alnylam Promotes Pushkal Garg to Chief Research and Development Officer - citybiz
Alnylam appoints Pushkal Garg as chief research and development officer - Investing.com Australia
Alnylam appoints Pushkal Garg as chief research and development officer By Investing.com - Investing.com Nigeria
Alnylam (ALNY) Names New Chief R&D Officer to Drive Innovation | - GuruFocus
Alnylam Announces Promotion of Pushkal Garg to Chief Research an - GuruFocus
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire
Alnylam Pharmaceuticals stock hits all-time high at $311.24 By Investing.com - Investing.com Canada
Global RNAi Technology Market: Opportunities in Targeted - openPR.com
Japan’s Isshiki bolsters life sciences practice with senior hire - | Asian Legal Business
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Antisense Oligonucleotides Market is expected to reach US$ - openPR.com
Exploring High Growth Tech Stocks In The US This June 2025 - simplywall.st
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com Canada
Acute Intermittent Porphyria Market Predicted to See Upsurge - openPR.com
From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals
Where are the Opportunities in (ALNY) - news.stocktradersdaily.com
Primary Hyperoxaluria Pipeline 2025: FDA Updates, Therapy - openPR.com
Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals
ALNY Stock: JP Morgan Raises Price Target to $338 | ALNY Stock N - GuruFocus
What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga
Homozygous Familial Hypercholesterolemia Market to Reach New - openPR.com
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail
JPMorgan Ups Price Target for Alnylam (ALNY) Following Amvuttra Forecast Revision | ALNY Stock News - GuruFocus
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
The European Commission Approves Alnylam’s AMVUTTRA - Insider Monkey
John Maraganore joins Axion Bio board to advance cancer therapy By Investing.com - Investing.com Canada
Former Alnylam CEO Who Built $40B Company Backs Instil Bio's Novel Cancer Drug Program - Stock Titan
EC approves Alnylam’s vutrisiran for ATTR-CM treatment - Yahoo Finance
Latest Federal Court Cases: Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. - JD Supra
Dyslipidemia Market to Reach New Heights in Growth by 2034, - openPR.com
Alnylam gets EU approval for Amvuttra in heart disorder treatment - MSN
Alnylam Receives European Commission Approval for AMVUTTRA® (vut - GuruFocus
European Approval Expansion for Alnylam's (ALNY) AMVUTTRA | ALNY Stock News - GuruFocus
Alnylam (ALNY) Secures EU Approval for Amvuttra in Cardiomyopathy - GuruFocus
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy - MarketScreener
EC approves first RNAi therapy for ATTR cardiomyopathy By Investing.com - Investing.com Nigeria
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy | ALNY Stock News - GuruFocus
(vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
siRNA on the Precipice as Candidates Reach Beyond the Liver - BioSpace
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - mx.advfn.com
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech
Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam - Life Sciences Intellectual Property Review
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga
Alnylam Fails to Revive Patent Infringement Suit Against Moderna - Bloomberg Law News
Strict Standard for Overriding Patent Lexicography in COVID Vaccine Patent Battle - Patently-O
CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’ - IPWatchdog.com
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Option Exercise |
118.73 |
19,297 |
2,291,057 |
68,245 |
| Greenstreet Yvonne | Chief Executive Officer |
May 30 '25 |
Sale |
304.39 |
31,640 |
9,630,902 |
48,948 |
| Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Sale |
306.00 |
19,297 |
5,904,882 |
48,948 |
0.49%
0.34%
자본화:
|
볼륨(24시간):